147 related articles for article (PubMed ID: 25456375)
1. FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
Heinemann V; Stintzing S
Lancet Oncol; 2014 Dec; 15(13):e583-e584. PubMed ID: 25456375
[No Abstract] [Full Text] [Related]
2. FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Price TJ; Townsend AR; Peeters M
Lancet Oncol; 2014 Dec; 15(13):e582-e583. PubMed ID: 25456374
[No Abstract] [Full Text] [Related]
3. FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Pietrantonio F; Iacovelli R; Di Bartolomeo M; de Braud F
Lancet Oncol; 2014 Dec; 15(13):e581. PubMed ID: 25456372
[No Abstract] [Full Text] [Related]
4. FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Petrelli F; Coinu A; Barni S
Lancet Oncol; 2014 Dec; 15(13):e581-e582. PubMed ID: 25456373
[No Abstract] [Full Text] [Related]
5. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab or bevacizumab in metastatic colorectal cancer?
Sclafani F; Cunningham D
Lancet Oncol; 2014 Sep; 15(10):1040-1. PubMed ID: 25088941
[No Abstract] [Full Text] [Related]
7. Gastrointestinal cancer: FOLFIRI plus cetuximab--preferred first-line treatment for mCRC.
Hutchinson L
Nat Rev Clin Oncol; 2014 Oct; 11(10):560. PubMed ID: 25135366
[No Abstract] [Full Text] [Related]
8. New combinations in metastatic colorectal cancer: what are our expectations?
Hurwitz H
Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
[No Abstract] [Full Text] [Related]
9. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
[TBL] [Abstract][Full Text] [Related]
10. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Li J
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
[No Abstract] [Full Text] [Related]
11. FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
Rahman A
Lancet Oncol; 2014 Dec; 15(13):e590. PubMed ID: 25499288
[No Abstract] [Full Text] [Related]
12. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Maspero F; Sauta MG; Beretta GD; Barni S
Clin Colorectal Cancer; 2013 Sep; 12(3):145-51. PubMed ID: 23763824
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
14. [Utilizing synergism].
Krankenpfl J; 2005; 43(4-6):145. PubMed ID: 16171088
[No Abstract] [Full Text] [Related]
15. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
16. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Saltz LB
Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
[No Abstract] [Full Text] [Related]
17. Two new drugs for colon cancer.
Med Lett Drugs Ther; 2004 Jun; 46(1184):46-8. PubMed ID: 15184808
[No Abstract] [Full Text] [Related]
18. Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Chan E; Kwak EL; Hwang J; Heiskala M; de La Bourdonnaye G; Mita M
Cancer Chemother Pharmacol; 2015 Apr; 75(4):701-9. PubMed ID: 25627002
[TBL] [Abstract][Full Text] [Related]
19. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.
Halama N; Herrmann C; Jaeger D; Herrmann T
Anticancer Res; 2008; 28(6B):4111-5. PubMed ID: 19192669
[TBL] [Abstract][Full Text] [Related]
20. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
Smith D; Bosacki C; Merrouche Y
Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
